Skip to content
Investors are constantly on the lookout for the next big thin sector which will usher in a wave of change in society. Companies in these sectors have the potential to be the next big thing in the market. Robotics stocks are one such emerging sector.
Robotics will change society in profound ways, or that is, they will continue to do so. They’re already involved in manufacturing of course, but also in medical and aerospace applications and beyond. The 7 Top Robinhood Stocks for October Bearing that in mind, here are 7 innovative robotics stocks to buy for future profits:InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Intuitive Surgical (NASDAQ:ISRG)
Brooks Automation (NASDAQ:BRKS)
ABB (NYSE:ABB)
Stryker (NYSE:SYK)
Accuray (NASDAQ:ARAY)
Raytheon (NYSE:RTX)
AeroVironment (NASDAQ:AVAV)
All of these stocks have serious growth potential from current levels. Innovative Robotics Stocks to Buy: Intuitive Surgical (ISRG)
Source: Sundry Photography / Shutterstock.com Intuitive Surgical is usually the first name investors think of when the topic...
Markets reeled from the revelation that President Donald Trump has tested positive for Covid-19, and that the economy created fewer-than-expected jobs last month....
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that......
On Friday, House Speaker Nancy Pelosi asked airlines to hold off on laying off more workers as stimulus was ‘being advanced’ to the industry. This comes as the Democrats saw their $2.2 trillion dollar package under the Heroes Act pass the House and President Trump tests positive for coronavirus. Yahoo Finance’s Jess Smith joins The Final Round to discuss the latest from Washington D.C....
The top electric vehicle manufacturers reported strong vehicle deliveries in the third quarter. Friday brought delivery numbers from EV pioneer Tesla Inc (NASDAQ: TSLA), and two of China's rising startups, Li Auto Inc. (NASDAQ: LI) and Nio Inc - ADR (NYSE: NIO).Given that Tesla doesn't break down monthly figures, here's how each of these companies fared in the quarter. Strong Across-The-Board EV Delivery Growth: Reflecting the solid interest in EVs, each of the companies reported strong double-digit quarter-over-quarter growth.Tesla sells globally, while Nio and Li's sales are confined to the Chinese market. It should also be noted that Tesla does not issue a geographic breakdown of delivery numbers. Sequentially, Tesla's growth outdid that of its Chinese rivals.Yet the strong increase should be taken with a pinch of salt. Pressured by factory shutdowns and the COVID-19 impact on consumers, Tesla's deliveries declined about 6.5% year-over-year in the second quarter.Tesla's production stood at...
As Tuesday of this week came and went, truck drivers gained several new benefits from changes to hours-of-service (HOS) regulations. One significant change is the split-sleeper berth exception.Tuesday's change is not technically new to the HOS regulations but rather an addition to the existing rule. Previously, drivers could utilize a split-sleeper berth exception in an 8/2 split. The new option adds a 7/3 split.It's unclear how many drivers utilized the provision before, and it's even more uncertain how many will use the new option.Inside hours-of-service changes: How driver productivity, safety benefitAdjustments to the 30-minute break and split-sleeper use could boost driver productivity and reduce violations.Click to read more"If the driver is properly trained on the split-break exception and is using an ELD (electronic logging device) that has split logging built into its rule set, the odds of the driver making an error and receiving a citation are fairly low," Tom Bray,...
11 months ago, the U.S. Food and Drug Administration (FDA) shut down Solid Biosciences' (SLDB) "IGNITE DMD" Phase I/II clinical trial after one of the young patients involved in the trial suffered a "serious adverse event." Despite the patient in question recovering, no new patients suffering such serious adverse events, and the company providing the FDA with "information and measures intended to improve patient safety" and "data related to manufacturing process improvements," the FDA declined to allow trials to resume in July, and asked Solid Biosciences to provide even more information on its trials, and on the safety measures it proposed to add to get the trials back on track.Fast forward three more months and -- success!On Thursday, Solid Biosciences confirmed that the FDA has "lifted the clinical hold" on its trials, acknowledging that the company has "satisfactorily addressed all clinical hold questions." Going forward, the company plans to remove most...
